The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,837,644 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding will support "Translational Studies for Targeted Alpha-Particle Therapy for Rare Melanomas" over a 4-year period from September 1, 2023 to August 31, 2027. This project grant aims to advance research into innovative cancer therapies, specifically exploring the use of targeted alpha-particle treatments for rare forms of melanoma. As a National Cancer Institute-designated comprehensive cancer center, Moffitt Cancer Center has significant expertise in cancer biology, immunotherapy, and clinical trials that will be leveraged to execute this research initiative.
Generated 6/11/24, 1:52 AM